Alemtuzumab in MS

In patients with relapsing-remitting MS, alemtuzumab was found to be superior to interferon beta 1-a . Patients were randomized to 12 mg of alemtuzumab for 5 days at month 0 and 3 days at month 12 by infusion or 44 mcg qod with interferon beta 1-a.

Neurology 2012;78:(14):1069-1078

Lancet Neurology 2011;10(4):338-348